What amount sold does Asaph, Inc. report in Form D filings?

The latest linked filings report $6K sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Asaph, Inc.'s most recent SEC filing?

Asaph, Inc.'s most recent Form D filing was on 2020-01-14.

How many investors does Asaph, Inc. have?

The most recent Form D filing lists 39 investor(s).

What type of securities does Asaph, Inc. offer?

Asaph, Inc.'s SEC Form D filings indicate equity offerings.

Asaph, Inc.

CIK: 0001798794·Biotechnology·SANTA FE, NM·Corporation·Founded 2019

Reported Sold

$6,077

Total Filings

Identified Offerings

Last Filed

Jan 14, 2020

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jan 14, 2020Form D — New notice

Reported sold: $6,077 · Target: $6,077

Rule 506(b)·39 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 1 identified offering

$6,077

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Thomas R. Nickoloff

Related Person

Appears on 1 filing

Alexander Koglin

Related Person

Appears on 1 filing

Michael Humbert

Related Person

Appears on 1 filing

David Seldin

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Jan 14, 2020	New	$6,077	$6,077	39

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Biuveris, Inc.

Biotechnology

Offering target: $6,077

Filed Jan 14, 2020